Actively Recruiting

Phase 4
Age: 9Months - 36Months
All Genders
Healthy Volunteers
NCT06020716

Antibiotics, Microbiology and Immunology in Children With Chronic Wet Cough - the AMIC Study

Led by Helse Stavanger HF · Updated on 2024-12-27

350

Participants Needed

7

Research Sites

245 weeks

Total Duration

On this page

Sponsors

H

Helse Stavanger HF

Lead Sponsor

O

Oslo University Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

The AMIC study is a double-blind, placebo-controlled, multicenter, nationwide, randomized controlled academic pharmaceutical trial. OVERALL PRIMARY OBJECTIVES: * To study the clinical efficacy of antibiotics in children with chronic wet cough (CWC). * To study if duration of treatment with antibiotics in children with CWC has impact on efficacy or time to relapse of symptoms. OVERALL SECONDARY OBJECTIVE: -To study respiratory pathogens and the diversity/composition of airway and gut microbiome in children with CWC compared to healthy controls, and changes in pathogens/microbiome after treatment with antibiotics. OVERALL TERTIARY OBJECTIVE: -To study the role of inflammation, immunology, and genetics in children with chronic wet cough and suspicion of PBB to increase the knowledge of pathophysiological mechanisms associated with PBB. The study will include two different RCTs AMIC 1 and AMIC 2: AMIC 1: Participants will be randomly assigned to 14 days amoxicillin-clavulanate syrup or placebo. AMIC 2: Participants will be randomly assigned 1:1 to receive either 14 or 28 days with amoxicillin-clavulanate syrup.

CONDITIONS

Official Title

Antibiotics, Microbiology and Immunology in Children With Chronic Wet Cough - the AMIC Study

Who Can Participate

Age: 9Months - 36Months
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 9 months to less than 36 months
  • Body weight between 7 kg and less than 24 kg
  • Born at term with gestational age 37 weeks or more
  • Chronic wet cough lasting more than 4 weeks with an average cough score of 4 or higher in the last 7 days
  • Written informed consent obtained from both parents
  • Eligible for treatment with Augmentin as assessed by the study team
Not Eligible

You will not qualify if you...

  • Born before 37 weeks of gestation
  • Acute upper or lower airway infection within the last 2 weeks
  • Other viral or bacterial infections within the last 2 weeks
  • Fever above 38 degrees Celsius within the last 2 weeks
  • Diagnosed chronic lung diseases such as cystic fibrosis, primary ciliary dyskinesia, interstitial lung disease, asthma, immunodeficiency, or esophagus atresia
  • Cardiac disease except for persisting foramen ovale or ductus arteriosus
  • Severe feeding problems or aspiration
  • Suspected or confirmed gastroesophageal reflux
  • Suspicion of enlarged tonsils or adenoids
  • Episodes suggesting asthma
  • Gross neurodevelopmental delay or suspected neurological disease
  • Known or suspected allergy to amoxicillin-clavulanate or other betalactams
  • Episodes of unexplained coughing up blood
  • Radiographic changes other than perihilar changes on screening x-ray
  • Signs of digital clubbing, low oxygen, chest deformity, or breathing difficulty at rest
  • Parents unable to speak or understand Norwegian
  • Systemic antibiotic use within the last 6 months
  • Participation in another clinical intervention trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Ålesund Hospital

Ålesund, Norway

Actively Recruiting

2

Haukeland University Hospital

Bergen, Norway

Actively Recruiting

3

Akershus University Hospital

Lillestrøm, Norway

Actively Recruiting

4

Oslo University Hospital

Oslo, Norway

Actively Recruiting

5

Stavanger University Hospital

Stavanger, Norway, 40

Actively Recruiting

6

University Hospital of North-Norway

Tromsø, Norway

Actively Recruiting

7

Trondheim University Hospital

Trondheim, Norway

Actively Recruiting

Loading map...

Research Team

K

Knut Øymar, MD PhD

CONTACT

I

Ingvild B Mikalsen, MD PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here